Posts

Posted on

Consonance-HFW Acquisition Corp. Announces Pricing of Its Initial Public Offering

Consonance-HFW Acquisition Corp. Announces Pricing of Its Initial Public Offering

NEW YORK–(BUSINESS WIRE)–
Consonance-HFW Acquisition Corp. (“Consonance-HFW”) announced today the pricing of its initial public offering of 8,000,000 units, at a price to the public of $10.00 per unit, for aggregate gross proceeds of $80,000,000. Each unit consists of one Class A ordinary share and one-third of one redeemable warrant, with each whole warrant entitling the holder thereof to purchase one Class A ordinary share. The units are expected to begin trading on the New York Stock Exchange on November 19, 2020 under the symbol “CHFW.U”. The offering is expected to close on November 23, 2020, subject to customary closing conditions.

Consonance-HFW is a newly incorporated blank check company, incorporated as a Cayman Islands exempted company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities, which we refer to as our initial business combination. While Consonance-HFW may acquire a company in any industry, it expects that its focus will be on the healthcare industry, particularly the biotechnology sector, in developed countries including, but not limited to, the United States and countries in Europe.

J.P. Morgan Securities LLC is acting as the sole book-running manager for the offering. Consonance-HFW has granted the underwriter a 45-day option to purchase up to an additional 1,200,000 units at the initial offering price to cover over-allotments, if any.

The offering of these securities is being made only by means of a prospectus. Copies of the prospectus relating to this offering, when available, may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, by telephone at (866) 803-9204 or by email at [email protected].

A registration statement relating to the sale of these securities was filed with, and declared effective by, the Securities and Exchange Commission. Copies of the registration statement can be accessed through the Securities and Exchange Commission’s website at www.sec.gov. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Forward Looking Statements

This press release contains statements that constitute “forward-looking statements,” including with respect to Consonance-HFW’s offering and search for an initial business combination. No assurance can be given that the offering will be completed on the terms described, or at all. Forward-looking statements are subject to numerous risks and conditions, many of which are beyond the control of Consonance-HFW, including those set forth in the Risk Factors section of Consonance-HFW’s registration statement relating to the offering. Consonance-HFW undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Joshua House

Consonance-HFW Acquisition Corp.

[email protected]

KEYWORDS: Caribbean United States Cayman Islands North America New York

INDUSTRY KEYWORDS: Biotechnology Health Professional Services Other Professional Services Small Business

MEDIA:

Logo
Logo
Posted on

Group 1 Automotive to Present at Stephens Annual Investment Conference 2020

PR Newswire

HOUSTON, Nov. 18, 2020 /PRNewswire/ — Group 1 Automotive, Inc. (NYSE: GPI), (“Group 1” or the “Company”), an international, Fortune 500 automotive retailer, today announced that senior management will present at the Stephens Annual Investment Conference 2020 on Thursday, November 19, 2020.  The virtual conference presentation is scheduled to begin at 3:00 p.m. E.T.

A softcopy of the Company’s presentation material provided at the virtual conference will also be available within http://www.group1corp.com/events and within the Investor Relations section of Group 1’s website at http://group1corp.com/company-presentations. 


About Group 1 Automotive, Inc.


Group 1 owns and operates 185 automotive dealerships, 241 franchises, and 49 collision centers in the United States, the United Kingdom and Brazil that offer 31 brands of automobiles. Through its dealerships, the Company sells new and used cars and light trucks; arranges related vehicle financing; sells service contracts; provides automotive maintenance and repair services; and sells vehicle parts.

Investors please visit www.group1corp.com, www.group1auto.com, www.group1collision.com, www.facebook.com/group1auto, and www.twitter.com/group1auto, where Group 1 discloses additional information about the Company, its business, and its results of operations.

Investor contacts:

Sheila Roth

Manager, Investor Relations
Group 1 Automotive, Inc.
713-647-5741 | [email protected]

Media contacts:

Pete DeLongchamps

Senior V.P. Manufacturer Relations, Financial Services and Public Affairs
Group 1 Automotive, Inc.
713-647-5770 | [email protected]
or
Clint Woods
Pierpont Communications, Inc.
713-627-2223 | [email protected]

 

Cision View original content:http://www.prnewswire.com/news-releases/group-1-automotive-to-present-at-stephens-annual-investment-conference-2020-301176541.html

SOURCE Group 1 Automotive, Inc.

Posted on

Quest Diagnostics Declares Quarterly Cash Dividend

PR Newswire

SECAUCUS, N.J., Nov. 18, 2020 /PRNewswire/ — Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.56 per share, payable on February 3, 2021 to shareholders of record of Quest Diagnostics common stock on January 20, 2021.

About Quest Diagnostics
Quest Diagnostics empowers people to take action to improve health outcomes. Derived from the world’s largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. Quest Diagnostics annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our 47,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives. www.QuestDiagnostics.com.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/quest-diagnostics-declares-quarterly-cash-dividend-301176537.html

SOURCE Quest Diagnostics

Posted on

Owens & Minor Prepares for Flu Season with Increased Made-in-Americas Mask and N95 Respirator Capacity

Owens & Minor Prepares for Flu Season with Increased Made-in-Americas Mask and N95 Respirator Capacity

For the past 20 years, global healthcare manufacturer’s HALYARD-branded product line of masks and N95 respirators has ranked at the top of the facial protection market

RICHMOND, Va.–(BUSINESS WIRE)–
As the United States prepares to enter flu season under the persistent COVID-19 pandemic, Owens & Minor (NYSE: OMI), the nation’s leading producer of medical-grade facial protection products, continues to increase production and invest in its capacity to provide frontline workers with procedure masks and N95 respirators.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201118006135/en/

Owens & Minor's HALYARD-branded Surgical N95 Respirators are made to protect frontline workers from airborne illnesses, which is why the form, fit and comfort are of utmost importance. (Photo: Business Wire)

Owens & Minor’s HALYARD-branded Surgical N95 Respirators are made to protect frontline workers from airborne illnesses, which is why the form, fit and comfort are of utmost importance. (Photo: Business Wire)

“At the onset of the COVID-19 pandemic, Owens & Minor acted with urgency and investment to deliver an increased supply of facial protection products, including procedure masks and N95 respirators,” said Edward A. Pesicka, President and CEO of Owens & Minor. “We are laser-focused on providing the highest quality products that are specifically designed for medical staff and essential workers. Frontline workers need protection now, and we are working tirelessly to meet that need.”

Since February, Owens & Minor has acted across four key categories and is poised to help support the nation’s critical facial protection needs:

  • Surgical N95 Respirators: Over 1000% increase in N95 production at three Americas locations, including additional manufacturing assets in Del Rio, Texas and Lexington, N.C.
  • Surgical and Procedure Masks: Nearly 100% increase in surgical and procedure mask production through new capital investment and improving efficiency of operations in Acuña, Mexico
  • Face Shields: Over 600% increase in face shields through new capital investment in Acuña, Mexico
  • Raw Materials: Additional, dedicated meltblown fabric manufacturing line in Lexington, N.C. to ensure end-to-end control of Owens & Minor supply chain, providing self-sufficiency from base material to finished mask—unlike other suppliers who rely on supply from Asia

The significant improvements across Owens & Minor’s facial protection categories were made possible by capital investments, improved rates of operation and increased production capacity to 24/7 shifts.

“Unlike many other manufacturers of facial protection products, Owens & Minor has more than a century of healthcare experience and is proud of our Americas-based manufacturing of medical-grade N95s dating to 1997,” said Pesicka. “We stand ready to provide protection for healthcare workers on the frontlines battling flu and COVID-19. Our Surgical N95 Respirators are made to protect frontline workers from airborne illnesses, which is why the form, fit and comfort of our respirators are of paramount importance.”

Owens & Minor’s HALYARD* FLUIDSHIELD* Surgical N95 Respirators are:

  • 100% Medical Grade: While the FDA has granted temporary emergency use authorization for some industrial grade N95s, HALYARD* FLUIDSHIELD* Surgical N95 Respirators are designed and manufactured in accordance with our own FDA cleared 510(k).
  • Made in the Americas, from Base Material to Finished Respirator: Unlike suppliers who rely on sources from Asia, all HALYARD* FLUIDSHIELD* Surgical N95s are manufactured in the Americas.
  • Highest Level of Protection: All HALYARD* FLUIDSHIELD* Respirators deliver Level 3 splash and spray protection—the highest recognized level of protection.
  • Specially Designed for Medical Staff and Essential Workers: The duckbill breathing chamber is more than twice as large as the leading surgical N95 respirator and exceeds NIOSH standards for breathability. Because proper snug fit is critical, HALYARD-brand N95s come in a range of sizes, with malleable nose wire to adjust fit. They have strong elastic straps that are securely bonded—not stapled—to the mask.
  • Reliably Supplied Every Day: With manufacturing investment and end-to-end control of its entire supply chain, Owens & Minor has been able to ramp up N95 production to consistently exceed customer historical usage levels even during the pandemic.

Owens & Minor proactively engages with AAMI, NIOSH and ASTM guideline panels to keep abreast of evolving standards and ensure the best protection provided by its products. The company holds over 30 patents in facial protection innovation.

About Owens & Minor

Owens & Minor, Inc. (NYSE: OMI) is a global healthcare solutions company with integrated technologies, products, and services aligned to deliver significant and sustained value for healthcare providers and manufacturers across the continuum of care. With over 15,000 dedicated teammates serving healthcare industry customers in 70 countries, Owens & Minor helps to reduce total costs across the supply chain by optimizing episode and point-of-care performance, freeing up capital and clinical resources, and managing contracts to optimize financial performance. A FORTUNE 500 company, Owens & Minor was founded in 1882 in Richmond, Virginia, where it remains headquartered today. The Company has distribution, production, customer service and sales facilities located across the Asia Pacific region, Europe, Latin America, and North America. For more information about Owens & Minor, visit owens-minor.com, follow @Owens_Minor on Twitter, and connect on LinkedIn at www.linkedin.com/company/owens-&-minor.

Jayme Maniatis

781-684-6610

[email protected]

KEYWORDS: United States North America Virginia

INDUSTRY KEYWORDS: Medical Supplies Health Medical Devices Infectious Diseases Hospitals Other Health General Health

MEDIA:

Logo
Logo
Photo
Photo
Owens & Minor’s HALYARD-branded Surgical N95 Respirators are made to protect frontline workers from airborne illnesses, which is why the form, fit and comfort are of utmost importance. (Photo: Business Wire)
Posted on

Sanderson Farms Announces Webcast Replay for Stephens Investment Conference

Sanderson Farms Announces Webcast Replay for Stephens Investment Conference

LAUREL, Miss.–(BUSINESS WIRE)–
Sanderson Farms, Inc. (NASDAQ: SAFM) made a virtual investor presentation today as a participant in the Stephens Annual Investment Conference. The link to the webcast that was originally posted to the Company’s website was incorrect and did not allow access to the live event for a portion of the presentation.

A replay of the entire investor presentation by Joe F. Sanderson, Jr., chairman and chief executive officer, and Mike Cockrell, treasurer, chief financial officer and chief legal officer, will be available by close of business on Friday, November 20, 2020. The link to the replay will be found at the investor relations section of the Company’s website, www.sandersonfarms.com, and will be available for a period of one year.

Sanderson Farms, Inc. is engaged in the production, processing, marketing and distribution of fresh, frozen and minimally prepared chicken. Its shares trade on the NASDAQ Global Select Market under the symbol SAFM.

Mike Cockrell

Treasurer, Chief Financial Officer &

Chief Legal Officer

(601) 649-4030

KEYWORDS: Mississippi United States North America

INDUSTRY KEYWORDS: Retail Agriculture Natural Resources Food/Beverage

MEDIA:

Logo
Logo
Posted on

NCLA Keeps Fighting Against Gov. Murphy’s Unlawful Effort to Rewrite Every Residential Lease in NJ

Matthew Johnson, et al. v. Governor Philip D. Murphy, et al.

Washington, D.C., Nov. 18, 2020 (GLOBE NEWSWIRE) — The New Civil Liberties Alliance, a nonpartisan, nonprofit civil rights group, today filed a response to the State’s motion to dismiss in the U.S. District Court for the District of New Jersey in the case of Matthew Johnson, et al. v. Governor Philip D. Murphy, et al. The lawsuit challenges Executive Order No. 128 (EO 128), which violates the Contracts Clause of the U.S. Constitution, as well as New Jersey’s Constitution and statutory laws, by interfering with freely negotiated contracts between tenants and housing providers.

NCLA clients like Mr. Johnson, who owns a small rental property in Cherry Hill, New Jersey, are property owners who rent out their homes to make a living. Most of them own only a single rental unit. The governor’s unconstitutional order victimizes them by allowing tenants to apply their security deposits to cover rent or back rent. The problem is that once a tenant uses up the security deposit in this way, that tenant no longer has a financial incentive to keep the property nice during the remainder of the tenancy, and it leaves the housing provider without any security against damage by the tenant.

Without statutory authority to do so, Governor Murphy purported to rewrite every residential lease in the State of New Jersey unilaterally. On its face EO 128 claims to waive numerous state laws governing security deposits that were adopted by proper, constitutional legislative process. Targeting a single group (i.e., residential tenants) for relief in this manner undermines freedom of contract, due process, and equal protection of the laws. It also ignores the governor’s limited role and disregards the separation of powers among branches of government.

The state’s move to dismiss the complaint for failure to state a claim is a feeble attempt to convince the court that the Contracts Clause, which prohibits states from adopting laws that interfere with contractual obligations, is a dead letter. New Jersey contends that once a state regulates an industry, it can then retroactively nullify any contractual provisions in that sector. Regulated businesses, even individuals who only rent out a single unit, the State argues, have no legitimate expectation against government intervention in their private contracts. 

NCLA’s response refutes the State’s absurd argument. EO 128 rewrites the terms of NCLA’s clients’ contracts, impairs the housing providers’ rights, and far exceeds any limited and temporary contractual interference that the Constitution might tolerate. EO 128 is precisely the type of state action the Framers designed the Contracts Clause to prohibit and is the kind that the Supreme Court has historically struck down. The security deposits for which the Plaintiffs contracted created an incentive for the tenants to comply with the terms of their leases and to maintain the condition of the housing providers’ properties. EO 128 created “every incentive” for the tenants to apply their deposit toward their rent and eliminate the security for which NCLA’s clients had contracted.

NCLA is asking the court to deny the State’s motion to dismiss and allow these New Jersey housing providers to continue pursuing their claims for declaratory and injunctive relief against Gov. Murphy.

NCLA released the following statements:

“It’s clear from the State’s motion to dismiss that Governor Murphy would like nothing more than to avoid judicial scrutiny of his unlawful executive order. And with good reason. EO 128 is a direct affront to the federal Contracts Clause, which exists to invalidate this sort of state interference with private contracts.”

— Jared McClain, Litigation Counsel, NCLA

“With one stroke of his pen, Governor Murphy single-handedly rewrote not only our clients’ lease agreements, but every existing residential lease in New Jersey. Governors are not dictators. He does not have the power to do this, and the U.S. Constitution specifically forbids him from doing this. Our clients are simply asking that their private contracts be respected and restored.”

— Kara Rollins, Litigation Counsel, NCLA

For more information visit case summary page
here
.

ABOUT NCLA

NCLA is a nonpartisan, nonprofit civil rights group founded by prominent legal scholar Philip Hamburger to protect constitutional freedoms from violations by the Administrative State. NCLA’s public-interest litigation and other pro bono advocacy strive to tame the unlawful power of state and federal agencies and to foster a new civil liberties movement that will help restore Americans’ fundamental rights.

 

 

 

###



Judy Pino, Communications Director
New Civil Liberties Alliance
202-869-5218
[email protected]

Posted on

Immutep Announces Expansion of TACTI-002 Collaboration Trial

  • Additional 74 patients with 1st line non-small cell lung cancer (NSCLC) to be enrolled, more than tripling patient numbers in this indication
  • Follows encouraging interim data from 1st line NSCLC patients
  • First Patient is expected to be enrolled in the expanded trial by the end of 2020
  • Separately, Immutep has initiated planning for a new randomized, controlled Phase II trial in 1st line Head and Neck Squamous Cell Carcinoma (HNSCC) advancing efti into late stage clinical trials in this indication

SYDNEY, Australia, Nov. 19, 2020 (GLOBE NEWSWIRE) — Immutep Limited (ASX: IMM; NASDAQ: IMMP) announces it is advancing clinical development for its lead product candidate eftilagimod alpha (“efti” or “IMP321”) through the expansion of its ongoing TACTI-002 study and a new Phase II trial.

TACTI-002 Expansion with Merck & Co, Inc., Kenilworth, NJ, USA

Immutep has expanded its collaboration trial with Merck & Co., Inc., Kenilworth, NJ, USA (known as “MSD” outside the United States and Canada) to include an additional 74 patients with 1st line NSCLC (Part A), the most advanced part of its ongoing Phase II TACTI-002 clinical trial evaluating efti with MSD’s KEYTRUDA® (pembrolizumab, an anti PD-1 treatment). The expansion extends Immutep’s existing clinical trial collaboration and supply agreement with MSD (announced on 12 March 2018).

Additional clinical sites will be added to the existing 12 study centres across Australia, Europe, and the US and the first patient is expected to be enrolled in the expanded trial by the end of 2020. The additional 74 patients in Part A will receive the same treatment regimen and dosing schedule.

The expansion follows the encouraging interim data presented at SITC as announced on 10th November 2020 including an Overall Response Rate (ORR) of 39.4% in evaluable patients (n=36), Disease Control Rate of 66.7% and two complete responses (complete disappearance of all lesions) from 1st line NSCLC patients enrolled in Part A. In addition, efti plus pembrolizumab continues to be safe and well tolerated with no new safety signals reported so far.

Immutep CEO, Marc Voigt said: “We are excited to expand our collaboration trial with MSD, one of the world’s leading immuno-oncology companies. The interim results reported from 1st line NSCLC patients have been consistently encouraging and signal good efficacy, particularly for low PD-L1 expressing patients who do not typically respond to immune checkpoint therapy. Not only does this give us great confidence expanding the TACTI-002 trial, but it also validates our strategy to form and grow multiple collaborations with innovative large pharma companies, such as MSD, that are seeking to augment the efficacy of their existing approved products, like Keytruda.”

Immutep Commences Planning for New Phase II Clinical Trial in Head and Neck Cancer

Separately, Immutep has commenced planning for a new Phase II, randomised, controlled clinical study in approximately 160 1st line HNSCC patients. Patients will be 1:1 randomised to receive efti in combination with an anti-PD-1 treatment, or anti-PD-1 monotherapy. The trial is intended to take place across clinical sites in the United States, Australia and Europe.

Immutep CEO, Marc Voigt said: “Efti has shown very encouraging results in head and neck cancer in the 2nd line setting with PD-X naïve patients as demonstrated by the results reported at SITC. This has given us great confidence to explore it as a therapy in the commercially more relevant 1st line therapy setting and we have initated planning for a new randomized clinical study. We hope to share additional details in the near future. This advances our development program into later stage clinical development.”

About the TACT-002 Trial

TACTI-002 (Two ACTive Immunotherapies) is being conducted in collaboration with Merck & Co., Inc., Kenilworth, NJ, USA (known as “MSD” outside the United States and Canada). The study is evaluating the combination of efti with MSD’s KEYTRUDA® (pembrolizumab) in up to 183 patients with second line head and neck squamous cell carcinoma or non-small cell lung cancer in first and second line.

The trial is a Phase II, Simon’s two-stage, non-comparative, open-label, single-arm, multicentre clinical study that is taking place in study centres across Australia, Europe, and the US.

Patients participate in one of the following:

  • Part A – First line Non-Small Cell Lung Cancer (NSCLC), PD-X naive
  • Part B – Second line NSCLC, PD-X refractory
  • Part C – Second line Head and Neck Squamous Cell Carcinoma (HNSCC), PD-X naive

TACTI-002 is an all comer study in terms of PD-L1 status, a well-known predictive marker for response to pembrolizumab monotherapy especially in NSCLC and HNSCC. PD-L1 expression is typically reported in three groups for NSCLC: < 1%, 1-49% and ≥ 50% (Tumour Proportion Score or TPS) and in HNSCC: < 1%, 1-19% and ≥ 20% (Combined Positive Score or CPS). Patients with a high PD-L1 status are typically more responsive to anti-PD-1 therapy such as pembrolizumab, whereas those with low PD-L1 status are overall significantly less responsive. Pembrolizumab monotherapy is registered in the US and the EU for first line NSCLC patients with a TPS score ≥ 1% (US) and ≥ 50% (EU), reflecting 65% and 30% of all first line NSCLC patients, respectively. Pembrolizumab monotherapy is registered in the US (regardless of PD-L1 expression) and EU (≥ 50% TPS score) for second line HNSCC patients.

More information about the trial can be found on Immutep’s website or on ClinicalTrials.gov (Identifier: NCT03625323)

About Immutep

Immutep is a globally active biotechnology company that is a leader in the development of LAG-3 related immunotherapeutic products for the treatment of cancer and autoimmune disease. Immutep is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders. Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States.

Immutep’s current lead product candidate is eftilagimod alpha (“efti” or “IMP321”), a soluble LAG-3 fusion protein (LAG-3Ig), which is a first-in-class antigen presenting cell (APC) activator being explored in cancer and infectious disease. Immutep is also developing an agonist of LAG-3 (IMP761) for autoimmune disease. Additional LAG-3 products, including antibodies for immune response modulation, are being developed by Immutep’s large pharmaceutical partners.

Further information can be found on the Company’s website www.immutep.com or by contacting:

Australian Investors/Media:

Catherine Strong, Citadel-MAGNUS
+61 (0)406 759 268; [email protected]

U.S. Media:

Tim McCarthy, LifeSci Advisors
+1 (212) 915.2564; [email protected]



Posted on

Roman DBDR Tech Acquisition Corp. Announces the Separate Trading of its Class A Common Stock and Warrants Commencing November 19, 2020

New York, New York, Nov. 18, 2020 (GLOBE NEWSWIRE) — Roman DBDR Tech Acquisition Corp. (the “Company”) announced today that, commencing November 19, 2020,  holders of the units sold in the Company’s initial public offering may elect to separately trade the shares of Class A common stock and warrants included in the units. Any units not separated will continue to trade on the Nasdaq Stock Market (the “Nasdaq”) under the symbol “DBDRU”, and the shares of Class A common stock and warrants will separately trade on the Nasdaq under the symbols “DBDR” and “DBDRW,” respectively. No fractional warrants will be issued upon separation of the units and only whole warrants will trade. Holders of units will need to have their brokers contact Continental Stock Transfer & Trust Company, the Company’s transfer agent, to separate the units into shares of Class A common stock and warrants.

A registration statement relating to these securities was declared effective by the U.S. Securities and Exchange Commission (the “SEC”) on November 5, 2020. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

The offering was made only by means of a prospectus. Copies of the prospectus relating to the offering may be obtained from B. Riley Securities, Inc. at 1300 17th Street N., Suite 1400, Attn: Syndicate Prospectus Department, Arlington, Virginia 22209, by telephone at (800) 846-5050 or by email at [email protected].


About Roman DBDR Tech Acquisition Corp.

Roman DBDR Tech Acquisition Corp. is a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. While the Company may pursue an initial business combination target in any stage of its corporate evolution or in any industry or sector, it intends to focus its search on companies in the technology, media and telecom (“TMT”) industries. The Company is led by its Co-Chief Executive Officers, Dr. Donald G. Basile and Dixon Doll, Jr.


Forward Looking Statements

This press release may contain forward-looking statements within the meaning of the federal securities laws. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company’s registration statement and prospectus for the offering filed with the SEC. Copies are available on the SEC’s website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Contact

Dr. Don Basile
Co-CEO and Chairman
[email protected]
(650) 618-2524



Posted on

BlackRock Enhanced Government Fund, Inc. Announces Expiration of Annual Repurchase Offer

BlackRock Enhanced Government Fund, Inc. Announces Expiration of Annual Repurchase Offer

NEW YORK–(BUSINESS WIRE)–
BlackRock Enhanced Government Fund, Inc. (the “Fund”) (NYSE: EGF, CUSIP: 09255K108) announced the expiration of the Fund’s annual repurchase offer for its shares of common stock (the “Repurchase Offer”). The Repurchase Offer and withdrawal rights expired at 5:00 p.m., Eastern Time, on November 18, 2020. The Fund offered to repurchase up to 10% of its issued and outstanding shares of common stock (the “Shares”) for cash at a price equal to the net asset value of the Shares as of the close of regular trading on the New York Stock Exchange on November 19, 2020, subject to a repurchase fee of 2% of the value of the Shares repurchased, which will be deducted from the repurchase price. As of Wednesday, November 18, 2020, 4,734,987 Shares of the Fund were outstanding. A repurchase amount of 10% of the Shares outstanding as of November 18, 2020 would represent approximately 473,498 Shares.

The preliminary count by Computershare Trust Company, N.A., the Fund’s depositary agent, indicated that approximately 1,202,530 Shares (approximately 25% of the Fund’s Shares outstanding as of November 18, 2020) were validly tendered and not withdrawn prior to the expiration of the Fund’s Repurchase Offer. This determination is subject to final confirmation and the proper delivery of all Shares tendered and not withdrawn.

Because the aggregate number of Shares tendered and not withdrawn exceeds the total number of Shares that the Fund offered to repurchase, the Fund will repurchase any Shares tendered on a pro rata basis. However, the Fund will accept all Shares tendered by stockholders who own, beneficially or of record, an aggregate of not more than 99 Shares and who tender all of their Shares, before pro rating Shares tendered by other stockholders. Shares validly tendered and accepted will not be entitled to receive any Fund dividend or distribution with a record date on or after November 24, 2020.

The Fund is a diversified, closed-end management investment company. The Fund’s investment objective is to provide stockholders with current income and gains.

None of the Fund, its investment adviser or its Board of Directors has made any recommendation to any stockholder as to whether to tender or refrain from tendering Shares in the Repurchase Offer.

For client-specific information regarding the Repurchase Offer, please contact your broker or financial advisor, or in the case of registered stockholders, Computershare Trust Company, N.A., which is acting as the depositary agent in connection with the Repurchase Offer.

About BlackRock

BlackRock helps investors build better financial futures. As a fiduciary to investors and a leading provider of financial technology, our clients turn to us for the solutions they need when planning for their most important goals. As of September 30, 2020, the firm managed approximately $7.81 trillion in assets on behalf of investors worldwide. For additional information on BlackRock, please visit www.blackrock.com | Twitter: @blackrock | Blog: www.blackrockblog.com | LinkedIn: www.linkedin.com/company/blackrock

Availability of Fund Updates

BlackRock will update performance and certain other data for the BlackRock closed-end funds (the “Funds”) on a monthly basis on its website in the “Closed-end Funds” section of www.blackrock.com as well as certain other material information as necessary from time to time. Investors and others are advised to check the website for updated performance information and the release of other material information about the Fund. This reference to BlackRock’s website is intended to allow investors public access to information regarding the Fund and does not, and is not intended to, incorporate BlackRock’s website in this release.

Forward-Looking Statements

This press release, and other statements that BlackRock or the Fund may make, may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act, with respect to the Fund’s or BlackRock’s future financial or business performance, strategies or expectations. Forward-looking statements are typically identified by words or phrases such as “trend,” “potential,” “opportunity,” “pipeline,” “believe,” “comfortable,” “expect,” “anticipate,” “current,” “intention,” “estimate,” “position,” “assume,” “outlook,” “continue,” “remain,” “maintain,” “sustain,” “seek,” “achieve,” and similar expressions, or future or conditional verbs such as “will,” “would,” “should,” “could,” “may” or similar expressions.

BlackRock cautions that forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and BlackRock assumes no duty to and does not undertake to update forward-looking statements. Actual results could differ materially from those anticipated in forward-looking statements and future results could differ materially from historical performance.

With respect to the Fund, the following factors, among others, could cause actual events to differ materially from forward-looking statements or historical performance: (1) changes and volatility in political, economic or industry conditions, the interest rate environment, foreign exchange rates or financial and capital markets, which could result in changes in demand for the Fund or in the Fund’s net asset value; (2) the relative and absolute investment performance of the Fund and its investments; (3) the impact of increased competition; (4) the unfavorable resolution of any legal proceedings; (5) the extent and timing of any distributions or share repurchases; (6) the impact, extent and timing of technological changes; (7) the impact of legislative and regulatory actions and reforms, including the Dodd-Frank Wall Street Reform and Consumer Protection Act, and regulatory, supervisory or enforcement actions of government agencies relating to the Fund or BlackRock, as applicable; (8) terrorist activities, international hostilities and natural disasters, which may adversely affect the general economy, domestic and local financial and capital markets, specific industries or BlackRock; (9) BlackRock’s ability to attract and retain highly talented professionals; (10) the impact of BlackRock electing to provide support to its products from time to time; and (11) the impact of problems at other financial institutions or the failure or negative performance of products at other financial institutions.

Annual and Semi-Annual Reports and other regulatory filings of the Fund with the Securities and Exchange Commission (“SEC”) are accessible on the SEC’s website at www.sec.govand on BlackRock’s website at www.blackrock.com, and may discuss these or other factors that affect the Fund. The information contained on BlackRock’s website is not a part of this press release.

BlackRock Closed-End Funds

1-800-882-0052

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Banking Professional Services Finance

MEDIA:

Posted on

MedAvail Completes $84 Million Private Placement Led by Ally Bridge Group

MedAvail Completes $84 Million Private Placement Led by Ally Bridge Group

MISSISSAUGA, Ontario & PHOENIX–(BUSINESS WIRE)–
MedAvail Holdings, Inc. (“MedAvail”), a leading technology-enabled pharmacy organization that embeds automated pharmacy services directly into clinics and other points of care through its proprietary technology, announced the completion of its private placement offering as part of its business combination announced on November 18, 2020. The private placement is being led by Ally Bridge Group (“ABG”) with participation from Cigna Ventures, Redmile Group, Pura Vida Investments, Adage Capital Management, Lewis and Clark Ventures, Heights Capital Management and Maven Investment Partners, among others.

MedAvail raised gross proceeds of approximately $84 million through the issuance and sale of securities in a private placement that closed prior to the consummation of the business combination and which ultimately resulted in the issuance of approximately 12.3 million shares of MedAvail’s common stock. Proceeds from the private placement will be used primarily to support strategic growth initiatives and for general corporate purposes.

Cowen and Company LLC acted as lead placement agent and Lake Street Capital Markets acted as a placement agent in the transaction.

“Over the last number of months, we have completed this financing that provides MedAvail with a strong financial platform to execute on our commercial strategies,” said Ed Kilroy, CEO of MedAvail. “We believe this is just the beginning; we are a transformational player in the pharmacy industry which is amid a major disruption. We feel uniquely positioned to take advantage of the opportunity.”

“The whole Ally Bridge team is thrilled to partner with Ed and the MedAvail team on this transaction,” said Frank Yu, Founder, CEO and CIO of ABG. “MedAvail has created a powerful automated in-clinic pharmacy platform for Medicare-focused care providers and retail clinics. Following the close of this financing, MedAvail is well-positioned to expand its footprint in the United States and build upon its value proposition of delivering instant and remote pharmacy services, better clinical outcomes, best in class patient medication compliance and satisfaction.”

About MedAvail

MedAvail is a technology-enabled pharmacy organization, providing turnkey in-clinic pharmacy services through its proprietary robotic dispensing platform, the MedAvail MedCenter, and home delivery operations, to Medicare clinics. MedAvail helps patients to optimize drug adherence, resulting in better health outcomes. Learn more at www.medavail.com.

About Ally Bridge Group

Ally Bridge Group (“ABG”), founded and led by Frank Yu (previously at Goldman Sachs and Och-Ziff Capital) and based in New York and Hong Kong, is a global healthcare investment firm focused on funding and supporting the world’s most innovative life science technologies benefiting many millions of human lives and leading high-impact transactions. Over the past five years, ABG has led over US $4 billion investments in world-leading life science companies in the U.S., China, Europe and Israel, across the medtech, tools and diagnostics, biotech and digital healthcare sectors. For more information, please visit www.ally-bridge.com.

Forward Looking Statements

Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook,” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding the company’s expected uses of proceeds from the business combination; potential future revenue and expansion plans; and market opportunity. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of MedAvail’s management and are not predictions of actual performance. Forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the forward-looking statements, including but not limited to general economic, financial, legal, political and business conditions and changes in domestic and foreign markets; the potential effects of COVID-19; the outcome of judicial proceedings to which MedAvail is, or may become a party; changes in competitive conditions prevailing in the healthcare sector; the availability of capital; and the other risks discussed under the heading “Risk Factors” in a Registration Statement on Form S-4 (“Form S-4”), which was declared effective by the SEC on October 15, 2020, and other documents MedAvail files with the SEC in the future. If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. These forward-looking statements speak only as of the date hereof and MedAvail specifically disclaims any obligation to update these forward-looking statements.

Investor Relations

Caroline Paul

Gilmartin Group

[email protected]

KEYWORDS: United States North America Arizona

INDUSTRY KEYWORDS: Software Other Health General Health Other Retail Professional Services Online Retail Internet Pharmaceutical Technology Retail Insurance Finance Health

MEDIA:

Logo
Logo